Format
Sort by

Send to

Choose Destination

Search results

Items: 9

1.

Cell Adhesion on Amyloid Fibrils Lacking Integrin Recognition Motif.

Jacob RS, George E, Singh PK, Salot S, Anoop A, Jha NN, Sen S, Maji SK.

J Biol Chem. 2016 Mar 4;291(10):5278-98. doi: 10.1074/jbc.M115.678177. Epub 2016 Jan 7.

PMID:
26742841
2.

The newly discovered Parkinson's disease associated Finnish mutation (A53E) attenuates α-synuclein aggregation and membrane binding.

Ghosh D, Sahay S, Ranjan P, Salot S, Mohite GM, Singh PK, Dwivedi S, Carvalho E, Banerjee R, Kumar A, Maji SK.

Biochemistry. 2014 Oct 21;53(41):6419-21. doi: 10.1021/bi5010365. Epub 2014 Oct 10.

PMID:
25268550
3.

MTA1-mediated transcriptional repression of SMAD7 in breast cancer cell lines.

Salot S, Gude R.

Eur J Cancer. 2013 Jan;49(2):492-9. doi: 10.1016/j.ejca.2012.06.019. Epub 2012 Jul 25.

PMID:
22841502
4.

Fascin overexpression promotes neoplastic progression in oral squamous cell carcinoma.

Alam H, Bhate AV, Gangadaran P, Sawant SS, Salot S, Sehgal L, Dange PP, Chaukar DA, D'cruz AK, Kannanl S, Gude R, Kane S, Dalal SN, Vaidya MM.

BMC Cancer. 2012 Jan 20;12:32. doi: 10.1186/1471-2407-12-32.

5.

Large scale expansion of Vgamma9Vdelta2 T lymphocytes from human peripheral blood mononuclear cells after a positive selection using MACS "TCR gamma/delta+ T cell isolation kit".

Salot S, Bercegeay S, Dreno B, Saïagh S, Scaglione V, Bonnafous C, Sicard H.

J Immunol Methods. 2009 Aug 15;347(1-2):12-8. doi: 10.1016/j.jim.2009.05.006. Epub 2009 May 22.

PMID:
19465023
6.

DNAX accessory molecule-1 (CD226) promotes human hepatocellular carcinoma cell lysis by Vgamma9Vdelta2 T cells.

Toutirais O, Cabillic F, Le Friec G, Salot S, Loyer P, Le Gallo M, Desille M, de La Pintière CT, Daniel P, Bouet F, Catros V.

Eur J Immunol. 2009 May;39(5):1361-8. doi: 10.1002/eji.200838409.

7.

IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human V gamma 9V delta 2 T cells for adoptive immunotherapy.

Thedrez A, Harly C, Morice A, Salot S, Bonneville M, Scotet E.

J Immunol. 2009 Mar 15;182(6):3423-31. doi: 10.4049/jimmunol.0803068.

8.

Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma.

Bennouna J, Bompas E, Neidhardt EM, Rolland F, Philip I, Galéa C, Salot S, Saiagh S, Audrain M, Rimbert M, Lafaye-de Micheaux S, Tiollier J, Négrier S.

Cancer Immunol Immunother. 2008 Nov;57(11):1599-609. doi: 10.1007/s00262-008-0491-8. Epub 2008 Feb 27.

PMID:
18301889
9.

Large scale expansion of gamma 9 delta 2 T lymphocytes: Innacell gamma delta cell therapy product.

Salot S, Laplace C, Saïagh S, Bercegeay S, Tenaud I, Cassidanius A, Romagne F, Dreno B, Tiollier J.

J Immunol Methods. 2007 Sep 30;326(1-2):63-75. Epub 2007 Aug 7.

PMID:
17716681
Items per page

Supplemental Content

Write to the Help Desk